Akari Therapeutics (AKTX) Return on Invested Capital (2016 - 2026)
Akari Therapeutics recorded quarterly Return on Invested Capital of 0.01% in Q1 2026, down 108.7% quarter-over-quarter from 0.01% in Q4 2025, and up 4.0% year-over-year from 0.01% in Q1 2025.
Akari Therapeutics' Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.01% for Q1 2026.
- In Q1 2026, Return on Invested Capital rose 4.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (up 4.0% YoY), while the FY2025 annual figure was 0.01%, changed N/A from the prior year.
- Return on Invested Capital came in at 0.01% for Q1 2026 at Akari Therapeutics, down from 0.01% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.01% in Q4 2025 to a low of 0.06% in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.01% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.05% |
| Dec 31, 2016 | -0.01% |
| Sep 30, 2016 | -0.01% |